A study by Indiana University researchers has identified 24 compounds -- including caffeine -- with the potential to boost an enzyme in the brain shown to protect against dementia. The research appeared March 7 in the journal Scientific Reports.
Specialized nerve cells, known as somatostatin-expressing (Sst) interneurons, in the outer part of the mammalian brain (or cerebral cortex) — play a key role in controlling how information flows in the brain when it is awake and alert. This is the finding of a study published online in Science March 2 by a team of neuroscientists at NYU Langone Medical Center and its Neuroscience Institute.
A Mayo Clinic research team has found a new gene mutation that may be a risk factor for late-onset Alzheimer’s disease in African-Americans.
NeuroVision Imaging LLC (“NeuroVision”) today announced its participation in a new substudy with investigators at the University of California San Diego School of Medicine (UC San Diego) and the University of Southern California (USC) to be part of the landmark Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (or “A4”) clinical trial. The purpose of the A4 study is to test whether a new investigational treatment that may reduce beta-amyloid accumulation in the brain can also slow memory loss caused by Alzheimer’s disease.
Donepezil, a medication that is approved to treat people with Alzheimer’s disease, should not be prescribed for people with mild cognitive impairment without a genetic test.
Researchers at the University of Illinois at Chicago College of Nursing have developed a free mobile app for individuals suffering from dementia, their families and caregivers, as a way to improve the quality-of-life, well-being and knowledge of the disease that affects nearly 48 million people worldwide.
Rush University Medical Center has launched a unique, cohort study called Latino Core to learn about the aging process and risk factors for Alzheimer’s disease in older Latino adults.
Cedars-Sinai neuroscientists have uncovered processes involved in how the human brain creates and maintains short-term memories. This study is the first clear demonstration of precisely how human brain cells work to create and recall short-term memories. Confirmation of this process and the specific brain regions involved is a critical step in developing meaningful treatments for memory disorders that affect millions of Americans.
Researchers from the UGR and UMA have designed a technique that aims to model high-level data abstractions to make computers learn to differentiate the brain of a healthy person from that of an ill person by extracting the affected regions.
Two Kennesaw State University scientists have received a total of $737,364 in National Science Foundation and National Institutes of Health grants for developmental biology research into autism and birth defects.
The latest study on hormone therapy and Alzheimer’s disease shows no relationship between taking the drugs and whether you may develop the disease years later. Some previous studies have shown that hormone therapy may increase the risk of the disease, while others have shown that it may reduce the risk. The new study was published in the February 15, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Calcium in the mitochondria -- the energy factory of cells -- may be one of the keys to understanding and treating Alzheimer's disease and dementia. Researchers at Temple University have now identified how an imbalance of calcium ions in the mitochondria may contribute to cell death and, specifically, neurodegeneration in brain cells during Alzheimer's and dementia. The findings could eventually point to new therapies for preventing or delaying these diseases. The team will present its work during the 61st Meeting of the Biophysical Society.
Currently, the predominant theory behind Alzheimer’s disease is the “amyloid hypothesis,” which states that abnormally increased levels of amyloid beta (Aβ) peptides outside of brain cells produce a variety of low molecular weight Aβ aggregates that are toxic to the nervous system. These Aβ aggregates interact directly with target cells and lead to cell death. During the Biophysical Society’s meeting, being held Feb. 11-15, 2017, Antonio De Maio will present his work hunting for the specific mechanisms behind Aβ-induced toxicity to cells, or cytoxicity.
Rutgers scientists say neurodegenerative diseases like Alzheimer’s and Parkinson’s may be linked to defective brain cells disposing toxic proteins that make neighboring cells sick. In a study published in Nature, Monica Driscoll, distinguished professor of molecular biology and biochemistry, School of Arts and Sciences, and her team, found that while healthy neurons should be able to sort out and rid brain cells of toxic proteins and damaged cell structures without causing problems, laboratory findings indicate that it does not always occur.
The loss of motor function and mental acuity associated with Huntington’s disease might be treatable by restoring a cellular quality control process, which Duke Health researchers have identified as a key factor in the degenerative illness.
A remembrance of Leon Thal, MD, an early giant of Alzheimer’s disease research and treatment by Howard Feldman, MDCM, current director of the Alzheimer’s Disease Cooperative Study at UC San Diego School of Medicine.
Leading neuroscientists have clarified the role of a controversial immune system protein in Alzheimer’s disease, showing it has opposing effects in early and late stages of the disease. Their discovery unites previous studies that left researchers conflicted and showed the protein both exacerbates and ameliorates disease symptoms. The updated model of disease progression, published in the Journal of Neuroscience, also highlights the need to align certain therapies with disease stages when treating the 1 in 9 Americans over 65 living with Alzheimer’s.
Photo Gallery: Magnet the Weight of 30 Elephants Lowered Through Roof of USC Stevens Hall for Next-Gen 7T MRI Machine
PHOENIX – Mayo Clinic researchers have found that engaging in mentally stimulating activities, even late in life, may protect against new-onset mild cognitive impairment, which is the intermediate stage between normal cognitive aging and dementia. The study found that cognitively normal people 70 or older who engaged in computer use, craft activities, social activities and playing games had a decreased risk of developing mild cognitive impairment. The results are published in the Jan. 30 edition of JAMA Neurology.
In some people, the brain protein tau collects into toxic tangles that damage brain cells and contribute to diseases such as Alzheimer’s. Researchers at Washington University School of Medicine in St. Louis have found a drug that can lower tau levels and prevent some neurological damage.
A clinical trial to examine the effect of nilotinib on clinical outcomes and biomarkers in people with mild to moderate Alzheimer’s disease has opened at Georgetown University Medical Center.
Xinglong Wang’s team published a study in the January 2017 issue of Molecular Therapy that is seen as confirming the relevance of this neurotoxic pathway, according to an accompanying editorial by Eloise Hudry, PhD, of the Alzheimer’s Disease Research Unit at Harvard Medical School. This paper also confirms TDP-43 inhibition as a viable therapeutic option for the treatment of neurologic disorders, including Alzheimer disease.
Promising, early studies of deep brain stimulation (DBS) for the treatment of Alzheimer’s disease have paved a path for future clinical trials, but there are unique ethical challenges with this vulnerable population regarding decision making and post-study treatment access that need to be addressed as they ramp up, Penn Medicine researchers argue in a new review in the Journal of Alzheimer’s Disease.
Older adults who suffer from arthritis need to keep moving to be functionally independent. But in an examination of a goal that is daunting for most of this aging population, a new Northwestern Medicine study found that performing even a third of the recommended activity is beneficial.
Researchers at Columbia University Medical Center have linked excess tau protein in the brain to the spatial disorientation that leads to wandering in many Alzheimer's disease patients. The findings, in mice, could lead to early diagnostic tests for Alzheimer's and point to treatments for this common and troubling symptom.
Research in mice points to better understanding of how the structure of nerve cells in the adult hippocampus may deteriorate, which can lead to Alzheimer’s disease and other neurological disorders.
When hospitalised, people can become acutely confused and disorientated. This condition, known as delirium, affects a quarter of older patients and new research by UCL and the University of Cambridge shows it may have long-lasting consequences, including accelerating the dementia process.
A synthesized steroid mirroring one naturally made by the dogfish shark prevents the buildup of a lethal protein implicated in some neurodegenerative diseases, reports an international research team studying an animal model of Parkinson’s disease. The clustering of this protein, alpha-synuclein (α-synuclein), is the hallmark of Parkinson’s and dementia with Lewy bodies, suggesting a new potential compound for therapeutic research.
Scientists at the University of Luxembourg have identified a gene that may provide a new starting point for developing treatments for Alzheimer's disease.
Sedentary older adults with no genetic risk factors for dementia may be just as likely to develop the disease as those who are genetically predisposed, according to a major study which followed more than 1,600 Canadians over five years.
Patients who had a diagnosis of Parkinson’s disease with dementia or dementia with Lewy bodies and had higher levels of Alzheimer’s disease pathology in their donated post-mortem brains also had more severe symptoms of these Lewy body diseases during their lives, compared to those whose brains had less AD pathology
The first study of its kind designed to test the effects of a diet on the decline of cognitive abilities among a large group of individuals 65 to 84 years who currently do not have cognitive impairment will begin in January.
Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration (FDA) that testing in humans may proceed for an investigational new drug after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
/PRNewswire-USNewswire/ -- The Institute for Functional Medicine (IFM) is pleased to announce a new collaboration with MPI Cognition, founded by Dale Bredesen, MD, to train clinicians in the treatment of mild cognitive impairment and early Alzheimer's disease. The program is titled Reversing Cognitive Decline: Advanced Clinical Training in Treating MCI and Early Alzheimer's Disease, and the first offering will be March 11-12, 2017, in Huntington Beach, CA.
Scientists at Washington University School of Medicine in St. Louis have detailed the structure of a molecule that has been implicated in Alzheimer’s disease. Knowing the shape of the molecule — and how that shape may be disrupted by certain genetic mutations — can help in understanding how Alzheimer’s and other neurodegenerative diseases develop and how to prevent and treat them.
Tests that measure the sense of smell may soon become common in neurologists’ offices. Scientists have been finding increasing evidence that the sense of smell declines sharply in the early stages of Alzheimer’s, and now a new study from the Perelman School of Medicine at the University of Pennsylvania published today in the Journal of Alzheimer’s Disease confirms that administering a simple “sniff test” can enhance the accuracy of diagnosing this dreaded disease
Ron Davis, chair of the Department of Neuroscience on the Florida campus of The Scripps Research Institute (TSRI) has been awarded a $5 million Outstanding Investigator Grant, one of the first of its kind, by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).
The holidays are supposed to be a time of joy and celebration, but we all know they can be stressful even under the best of circumstances. Add to the mix a relative with Alzheimer’s Disease (AD) or dementia, and caregivers and family members can quickly become overwhelmed.
An international team led by Washington University School of Medicine in St. Louis has selected a third investigational drug to be tested in a worldwide clinical trial – already underway – aimed at finding treatments to prevent Alzheimer’s disease.
Iowa State University researchers say higher levels of the enzyme, autotaxin, significantly predict memory impairment and Type 2 diabetes. The research published in the Journal of Alzheimer's Disease emphasizes the link between physical and mental health.
An expert at Rutgers University’s Care2Caregivers helpline shares tips on how families can celebrate the holidays with loved ones suffering from an illness that affects memory
• Risks of dementia and Alzheimer’s disease are higher in older kidney transplant recipients than in older adults in the general population. • Among kidney transplant recipients, those who developed dementia or Alzheimer’s disease had higher rates of organ loss and patient death than those who did not develop these conditions.
People who have protein in their urine, which is a sign of kidney problems, may also be more likely to later develop problems with thinking and memory skills or even dementia, according to a meta-analysis published in the December 14, 2016, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have discovered a molecular cause of hydrocephalus, a common, potentially life-threatening birth defect in which the head is enlarged due to excess fluid surrounding the brain. Because the same molecule is also implicated in Down’s syndrome, the finding, published today in the Journal of Neuroscience, may explain the ten-fold increased risk of hydrocephalus in infants born with Down’s.
Electrocranial stimulation offers hope for Alzheimer's patients
Commenting on a Financial Times feature on drug trials of the "plaque" theory of Alzheimer's---all of which have failed so far---Chris Norwood, in a lead letter, underscores that targeted diabetes prevention is really the major documented path to Alzheimer's prevention
According to renowned neurologist Oliver Sacks, “music can move us to the heights or depths of emotion, but the power of music goes much further.” To hear and experience music’s potential, members of the Rensselaer Polytechnic Institute campus and local community are invited to a multimedia concert and lecture focused on the links between music and health, sponsored by the Center for Biotechnology and Interdisciplinary Studies (CBIS) and the Department of the Arts. The event will be held on Dec. 8, from 4:30 to 6 p.m. in the Curtis R. Priem Experimental Media and Performing Arts Center (EMPAC) Concert Hall.
Measuring the brain activity of healthy, older adults while they walk and talk at the same time may help predict their risk of falls later, according to a study published in the December 7, 2016, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have made an important discovery toward the development of drugs to treat age-related memory loss in diseases like Alzheimer’s.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right